HMGCR and clostridium difficile infection: Although statin use has been associated with severe or complicated CDI in IBD patients [51], the higher rate of HMG-CoA reductase inhibitor use in the non-IBD group in our study can be explained by the older age and higher prevalence of hyperlipidemia and other comorbidities in these patients.